Lv4
496 积分 2026-02-16 加入
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
2天前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
2天前
已完结
Anti-tumor activity of camptothecin analog conjugate of an RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer
28天前
已完结
Identification of a Primary Target of Thalidomide Teratogenicity
1个月前
已完结
Exploring the next generation of antibody–drug conjugates
1个月前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
1个月前
已完结
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
3个月前
已关闭
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
3个月前
已关闭
New payloads drive next-gen antibody–drug conjugates
3个月前
已完结
Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes
4个月前
已完结
ZBTB20 promotes malignancy and stemness in lung squamous cell carcinoma through the transcriptional repression of KCTD1 and activation of Hedgehog signaling
皖公网安备34019202002308
